Cargando…

Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies

Microbial biofilms are becoming increasingly difficult to treat in the medical setting due to their intrinsic resistance to antibiotics. To combat this, several biofilm dispersal agents are currently being developed as treatments for biofilm infections. Combining biofilm dispersal agents with antibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawas, Sophia, Verderosa, Anthony D., Totsika, Makrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915430/
https://www.ncbi.nlm.nih.gov/pubmed/35281447
http://dx.doi.org/10.3389/fcimb.2022.850030
_version_ 1784668021431730176
author Hawas, Sophia
Verderosa, Anthony D.
Totsika, Makrina
author_facet Hawas, Sophia
Verderosa, Anthony D.
Totsika, Makrina
author_sort Hawas, Sophia
collection PubMed
description Microbial biofilms are becoming increasingly difficult to treat in the medical setting due to their intrinsic resistance to antibiotics. To combat this, several biofilm dispersal agents are currently being developed as treatments for biofilm infections. Combining biofilm dispersal agents with antibiotics is emerging as a promising strategy to simultaneously disperse and eradicate biofilms or, in some cases, even inhibit biofilm formation. Here we review studies that have investigated the anti-biofilm activity of some well-studied biofilm dispersal agents (e.g., quorum sensing inhibitors, nitric oxide/nitroxides, antimicrobial peptides/amino acids) in combination with antibiotics from various classes. This review aims to directly compare the efficacy of different combination strategies against microbial biofilms and highlight synergistic treatments that warrant further investigation. By comparing across studies that use different measures of efficacy, we can conclude that treating biofilms in vitro and, in some limited cases in vivo, with a combination of an anti-biofilm agent and an antibiotic, appears overall more effective than treating with either compound alone. The review identifies the most promising combination therapies currently under development as biofilm inhibition and eradication therapies.
format Online
Article
Text
id pubmed-8915430
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89154302022-03-12 Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies Hawas, Sophia Verderosa, Anthony D. Totsika, Makrina Front Cell Infect Microbiol Cellular and Infection Microbiology Microbial biofilms are becoming increasingly difficult to treat in the medical setting due to their intrinsic resistance to antibiotics. To combat this, several biofilm dispersal agents are currently being developed as treatments for biofilm infections. Combining biofilm dispersal agents with antibiotics is emerging as a promising strategy to simultaneously disperse and eradicate biofilms or, in some cases, even inhibit biofilm formation. Here we review studies that have investigated the anti-biofilm activity of some well-studied biofilm dispersal agents (e.g., quorum sensing inhibitors, nitric oxide/nitroxides, antimicrobial peptides/amino acids) in combination with antibiotics from various classes. This review aims to directly compare the efficacy of different combination strategies against microbial biofilms and highlight synergistic treatments that warrant further investigation. By comparing across studies that use different measures of efficacy, we can conclude that treating biofilms in vitro and, in some limited cases in vivo, with a combination of an anti-biofilm agent and an antibiotic, appears overall more effective than treating with either compound alone. The review identifies the most promising combination therapies currently under development as biofilm inhibition and eradication therapies. Frontiers Media S.A. 2022-02-25 /pmc/articles/PMC8915430/ /pubmed/35281447 http://dx.doi.org/10.3389/fcimb.2022.850030 Text en Copyright © 2022 Hawas, Verderosa and Totsika https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Hawas, Sophia
Verderosa, Anthony D.
Totsika, Makrina
Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies
title Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies
title_full Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies
title_fullStr Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies
title_full_unstemmed Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies
title_short Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies
title_sort combination therapies for biofilm inhibition and eradication: a comparative review of laboratory and preclinical studies
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915430/
https://www.ncbi.nlm.nih.gov/pubmed/35281447
http://dx.doi.org/10.3389/fcimb.2022.850030
work_keys_str_mv AT hawassophia combinationtherapiesforbiofilminhibitionanderadicationacomparativereviewoflaboratoryandpreclinicalstudies
AT verderosaanthonyd combinationtherapiesforbiofilminhibitionanderadicationacomparativereviewoflaboratoryandpreclinicalstudies
AT totsikamakrina combinationtherapiesforbiofilminhibitionanderadicationacomparativereviewoflaboratoryandpreclinicalstudies